The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

2 Aug 2012 12:12

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying Silence Therapeutics plc issuer of existing shares to which voting rights are attached: ii

2 Reason for the notification (please tick the appropriate box or boxes):An acquisition or disposal of voting rightsAn acquisition or disposal of qualifying financial instruments which mayresult in the acquisition of shares already issued to which votingrights are attachedAn acquisition or disposal of instruments with similar economic effectto qualifying financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):

3. Full name of person(s) subject to the Simpson Financial Limited notification obligation: iii

4. Full name of shareholder(s) (ifdifferent from 3.):iv5. Date of the transaction and date on 2 August 2012which the threshold is crossed orreached: v6. Date on which issuer notified: 2 August 20127. Threshold(s) that is/are crossed or below 3%

reached: vi, vii

8. Notified details:

A: Voting rights attached to shares viii, ixClass/type of Situation previous to Resulting situation after the triggeringshares if the triggering transactionpossible using transactionthe ISIN CODE Number of Number of Number of Number of voting % of voting rights Shares Voting shares rights x Rights Direct xi Direct Indirect Direct Indirect xiiGB0008433350 25,000,000 25,000,000 33,073,055 33,073,055 2.26%B: Qualifying Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration Exercise/ Number of voting % of votinginstrument date xiii Conversion Period rights that may be rights xiv acquired if the instrument is exercised/ converted.N/AC: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xviResulting situation after the triggering transactionType of Exercise Expiration Exercise/ Number of voting % of voting rightsfinancial price date xvii Conversion rights instrument xix, xxinstrument period refers to xviiiN/A Nominal Delta Total (A+B+C)Number of voting rights Percentage of voting rights33,073,055 2.26%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to holdvoting rights:13. Additional information:14. Contact name: Eric K. Simpson15. Contact telephone number: 852 2520 2066

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal Simpson Financial Limited entities) Contact address (registered office for Wyndham Place 26th Floor, 44 Wyndham legal entities)

Street, Central, Hong KongPhone number & email 852 2520 2066 sfl@simpsonfinancial.comOther useful information (at least legalrepresentative for legal persons)B: Identity of the notifier, if applicableFull nameContact addressPhone number & emailOther useful information (e.g. functionalrelationship with the person or legalentity subject to the notificationobligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
26th Nov 20217:00 amRNSUpdate on AIM Delisting
25th Nov 20215:30 pmRNSSilence Therapeutics
16th Nov 20217:00 amRNSThird Quarter 2021 Financial Results
11th Nov 20217:00 amRNSSilence to Present at Jefferies London Conference
10th Nov 20217:00 amRNSHolding(s) in Company
5th Nov 20217:00 amRNSNew Key Shareholder
1st Nov 20215:33 pmRNSResult of General Meeting
1st Nov 20214:49 pmRNSTotal Voting Rights
28th Oct 20214:02 pmRNSHolding(s) in Company
21st Oct 20211:30 pmRNSSilence Provides Pipeline Updates at 2021 R&D Day
15th Oct 20217:05 amRNSProposed Cancellation of Trading on AIM
15th Oct 20217:00 amRNSSilence and Hansoh Pharma Announce Collaboration
8th Oct 20217:00 amRNSBlock Listing Return
8th Oct 20217:00 amRNSTotal Voting Rights
7th Oct 20217:00 amRNSSilence Therapeutics to host R&D day
28th Sep 20217:00 amRNSChardan Genetic Medicines Conference Participation
8th Sep 20214:03 pmRNSHolding(s) in Company
8th Sep 20214:00 pmRNSHolding(s) in Company
1st Sep 20217:00 amRNSSilence Appoints Senior VP of BD, AM and NPD.
25th Aug 20217:00 amRNSSilence to Participate in Investor Conferences
12th Aug 20217:00 amRNSSilence Therapeutics Report Half-Year 2021 Results
6th Aug 202112:15 pmRNSHolding(s) in Company
6th Aug 202112:13 pmRNSHolding(s) in Company
5th Aug 20212:57 pmRNSTotal Voting Rights
15th Jul 20217:00 amRNSNotice of half year results
15th Jun 20215:54 pmRNSResults of Annual General Meeting
7th Jun 20217:00 amRNSSilence to present SL124 data at EHA
25th May 20217:00 amRNS$40m Payment from AstraZeneca for Collaboration
19th May 20217:00 amRNSPhase 1 Study in Healthy Volunteers Positive Data
12th May 20217:00 amRNSSilence attends RBC Global Healthcare Conference
7th May 20217:00 amRNSNotice of AGM
4th May 20217:00 amRNSSilence Support International Thalassemia Day
30th Apr 20214:12 pmRNSHolding(s) in Company
29th Apr 20215:58 pmRNSHolding(s) in Company
29th Apr 20217:00 amRNSFirst patient dosed in GEMINI II
28th Apr 20217:00 amRNSSilence Achieves Research Milestone Payment
27th Apr 20217:00 amRNSGrant of Employee Options
19th Apr 20217:00 amRNSPurchase of ADS and PDMR Shareholding
15th Apr 20217:00 amRNSPublication in Cardiovascular Research
7th Apr 20217:00 amRNSSilence to Present at Virtual Needham Conference
30th Mar 20216:13 pmRNSSilence Therapeutics Publication of Annual Report
30th Mar 20219:04 amRNSREPLACEMENT Silence Reports Full-year 2020 Results
30th Mar 20217:00 amRNSSilence Reports Full-year 2020 Results
26th Mar 20217:00 amRNSBlock Listing Application
4th Mar 20217:29 amRNSSilence presents at Barclays Healthcare Conference
1st Mar 20217:00 amRNSNotice of Annual Results
26th Feb 20217:00 amRNSSilence & Mallinckrodt Initiate Work on 3rd Target
24th Feb 20213:09 pmRNSHolding(s) in Company
22nd Feb 20217:00 amRNSSilence to Partake in March Investor Conferences
18th Feb 20217:00 amRNSSilence to present at SVB Leerink Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.